Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker KPTI · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Nov 4, 2026 | Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis NCT04562389 · Myelofibrosis Selinexor, Selinexor | KPTI Karyopharm Therapeutics Inc | Phase 3 | Active, not recruiting | 353 | Feb 20, 2026 | Registry ↗ |
| Oct 29, 2026 | Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanc… NCT05611931 · Endometrial Cancer Selinexor, Matching Placebo for selinexor | KPTI Karyopharm Therapeutics Inc | Phase 3 | Active, not recruiting | 257 | May 22, 2026 | Registry ↗ |
| Oct 29, 2026 | A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM… NCT04414475 · Multiple Myeloma, Refractory Selinexor, Dexamethasone | KPTI Karyopharm Therapeutics Inc | Phase 2 | Recruiting | 127 | Jan 2028 | Registry ↗ |
| Oct 9, 2026 | Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepat… NCT04256707 · Non-Small Cell Lung Carcinoma (NSCLC), Colorectal Cancer (C… Selinexor 100 mg, Docetaxel | KPTI Karyopharm Therapeutics Inc | Phase 1/2 | Completed | 80 | Jul 31, 2024 | Registry ↗ |
| Oct 2, 2026 | A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patien… NCT04442022 · Relapsed/Refractory Diffuse Large B-cell Lymphoma Selinexor (combination therapy), Selinexor (combination the… | KPTI Karyopharm Therapeutics Inc | Phase 2/3 | Active, not recruiting | 501 | Dec 2026 | Registry ↗ |
| Oct 1, 2026 | Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) NCT02227251 · Diffuse Large B-cell Lymphoma Selinexor, Selinexor | KPTI Karyopharm Therapeutics Inc | Phase 2 | Active, not recruiting | 244 | Dec 2026 | Registry ↗ |
| Jul 15, 2026 | Selinexor and Backbone Treatments of Multiple Myeloma Patients NCT02343042 · Multiple Myeloma Selinexor, Dexamethasone | KPTI Karyopharm Therapeutics Inc | Phase 1/2 | Recruiting | 300 | Apr 2027 | Registry ↗ |
| Jul 2, 2026 | A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previousl… NCT04562870 · Myelofibrosis Selinexor, Physician's Choice Treatment | KPTI Karyopharm Therapeutics Inc | Phase 2 | Active, not recruiting | 112 | Sep 2026 | Registry ↗ |
| Apr 13, 2026 | Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial… NCT03555422 · Endometrial Cancer Selinexor, Matching placebo for selinexor | KPTI Karyopharm Therapeutics Inc | Phase 3 | Completed | 263 | Jan 22, 2022 | Registry ↗ |
| Mar 2, 2026 | Karyopharm Expanded Access Program for Selinexor NCT07215832 · Multiple Myeloma, Diffuse Large B-Cell Lymphoma (DLBCL) selinexor | KPTI Karyopharm Therapeutics Inc | — | Available | — | — | Registry ↗ |
| Feb 12, 2026 | A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Th… NCT05980806 · Myelofibrosis, Moderate Thrombocytopenia Selinexor 60 mg, Selinexor 40 mg | KPTI Karyopharm Therapeutics Inc | Phase 2 | Recruiting | 58 | Jun 2027 | Registry ↗ |
| Oct 3, 2025 | Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With… NCT04607772 · Relapsed or Refractory Diffuse Large B-Cell Lymphoma Selinexor, Rituximab | KPTI Karyopharm Therapeutics Inc | Phase 1/2 | Withdrawn | 0 | Dec 2025 | Registry ↗ |
| Mar 19, 2025 | Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory… NCT02649790 · Relapsed/Refractory Multiple Myeloma (RRMM), Metastatic Col… KPT-8602, ASTX727 | KPTI Karyopharm Therapeutics Inc | Phase 1/2 | Completed | 277 | Aug 31, 2024 | Registry ↗ |
| Dec 16, 2024 | A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent… NCT04421378 · Glioblastoma Multiforme Selinexor, Temozolomide (TMZ) | KPTI Karyopharm Therapeutics Inc | Phase 1/2 | Terminated | 74 | Jul 3, 2023 | Registry ↗ |
| Nov 25, 2024 | PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA) NCT02702492 · Solid Tumors, NHL KPT-9274, Niacin ER | KPTI Karyopharm Therapeutics Inc | Phase 1 | Terminated | 60 | Jan 26, 2021 | Registry ↗ |
| Aug 23, 2024 | Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma NCT04768881 · Locally Advanced Unresectable or Metastatic Melanoma Selinexor, Pembrolizumab | KPTI Karyopharm Therapeutics Inc | Phase 2 | Terminated | 15 | Sep 22, 2023 | Registry ↗ |
| Aug 21, 2024 | Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma NCT03110562 · Multiple Myeloma Selinexor, Bortezomib | KPTI Karyopharm Therapeutics Inc | Phase 3 | Completed | 402 | Feb 18, 2020 | Registry ↗ |
| Jan 8, 2024 | A Phase I Trial to Assess the Effects of Food and Formulation on PK of KPT-330 in Patients With Sar… NCT01896505 · Sarcoma KCP-330 | KPTI Karyopharm Therapeutics Inc | Phase 1 | Completed | 54 | Oct 21, 2016 | Registry ↗ |
| Nov 3, 2023 | A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Stand… NCT04854434 · Metastatic Colorectal Cancer Selinexor, Pembrolizumab | KPTI Karyopharm Therapeutics Inc | Phase 2 | Terminated | 13 | Jun 24, 2022 | Registry ↗ |
| Jan 26, 2023 | Selinexor, Carfilzomib, and Dexamethasone Versus Placebo, Carfilzomib, and Dexamethasone in Multipl… NCT02628704 · Multiple Myeloma Selinexor, Placebo (for selinexor) | KPTI Karyopharm Therapeutics Inc | Phase 2 | Withdrawn | 0 | Jun 2017 | Registry ↗ |
| Jan 26, 2023 | Efficacy & Safety Study of KPT-330 in Erythropoietin-Refractory Lower-Risk Myelodysplastic Syndrome… NCT02431351 · Myelodysplastic Syndrome Selinexor | KPTI Karyopharm Therapeutics Inc | Phase 2 | Withdrawn | 0 | Dec 2017 | Registry ↗ |
| Jan 26, 2023 | Study of Selinexor (KPT- 330), Lenalidomide, & Dexamethasone in Relapsed/Refractory Multiple Myelom… NCT02389543 · Multiple Myeloma Selinexor, Lenalidomide | KPTI Karyopharm Therapeutics Inc | Phase 1/2 | Withdrawn | 0 | Jan 2018 | Registry ↗ |
| Jan 26, 2023 | Selinexor Treatment of Refractory Myeloma NCT02336815 · Multiple Myeloma Selinexor, Dexamethasone | KPTI Karyopharm Therapeutics Inc | Phase 2 | Completed | 202 | Jul 26, 2019 | Registry ↗ |
| Jan 26, 2023 | Efficacy and Safety Study of Selinexor in Relapsed or Refractory Peripheral T-cell Lymphoma or Cuta… NCT02314247 · Peripheral T-cell Lymphoma (PTCL), Cutaneous T-cell Lymphom… Selinexor | KPTI Karyopharm Therapeutics Inc | Phase 2 | Terminated | 16 | Jan 2016 | Registry ↗ |
| Jan 26, 2023 | Selinexor Treatment of Advanced Relapsed/Refractory Squamous Cell Carcinomas NCT02213133 · Squamous Cell Carcinoma Selinexor (KPT-330) | KPTI Karyopharm Therapeutics Inc | Phase 2 | Terminated | 45 | Dec 10, 2015 | Registry ↗ |
| Jan 26, 2023 | SHIP (Selinexor in Hormone Insensitive Prostate Cancer) NCT02146833 · Prostate Cancer Selinexor | KPTI Karyopharm Therapeutics Inc | Phase 2 | Terminated | 20 | Apr 1, 2016 | Registry ↗ |
| Jan 26, 2023 | Selinexor in Initial or Refractory and/or Relapsed Richter's Transformation NCT02138786 · Richter's Transformation selinexor | KPTI Karyopharm Therapeutics Inc | Phase 2 | Terminated | 27 | Aug 31, 2016 | Registry ↗ |
| Jan 26, 2023 | Selinexor (KPT-330) in Older Patients With Relapsed AML NCT02088541 · Acute Myeloid Leukemia (AML) Selinexor, Hydroxyurea | KPTI Karyopharm Therapeutics Inc | Phase 2 | Completed | 317 | Jan 8, 2018 | Registry ↗ |
| Jan 26, 2023 | Study of KPT-330 (Selinexor) in Female Patients With Advanced Gynaecologic Malignancies NCT02025985 · Ovarian Carcinoma, Endometrial Carcinoma Selinexor | KPTI Karyopharm Therapeutics Inc | Phase 2 | Completed | 116 | Jan 24, 2017 | Registry ↗ |
| Jan 26, 2023 | Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Participants With Recurrent Glio… NCT01986348 · Glioblastoma, Glioma Selinexor | KPTI Karyopharm Therapeutics Inc | Phase 2 | Terminated | 76 | Jan 23, 2020 | Registry ↗ |
| Jan 26, 2023 | Safety Study of KPT-330 (Selinexor) in Patients With Advanced or Metastatic Solid Tumor Cancer NCT01607905 · Solid Tumor Selinexor, Acetaminophen | KPTI Karyopharm Therapeutics Inc | Phase 1 | Completed | 192 | Mar 15, 2016 | Registry ↗ |
| Jan 26, 2023 | Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced… NCT01607892 · Hematological Malignancies KPT-330 | KPTI Karyopharm Therapeutics Inc | Phase 1 | Completed | 286 | Oct 13, 2015 | Registry ↗ |
| Jan 23, 2023 | Selinexor in Advanced Liposarcoma NCT02606461 · Dedifferentiated Liposarcoma Selinexor, Placebo | KPTI Karyopharm Therapeutics Inc | Phase 2/3 | Completed | 342 | Oct 28, 2020 | Registry ↗ |
| Jan 20, 2023 | Evaluation of Activity and Safety of Two Regimens of Low Dose Oral Selinexor in Participants With M… NCT04355676 · Coronavirus Infection Selinexor | KPTI Karyopharm Therapeutics Inc | Phase 2 | Withdrawn | 0 | Aug 30, 2020 | Registry ↗ |
| Jan 20, 2023 | Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection NCT04349098 · Coronavirus Infection Selinexor, Placebo | KPTI Karyopharm Therapeutics Inc | Phase 2 | Completed | 190 | Oct 5, 2020 | Registry ↗ |
| Jan 20, 2023 | Trial of Safety and Tolerability of Oral Verdinexor (KPT-335) in Healthy Adults NCT02431364 · Healthy Verdinexor, Placebo | KPTI Karyopharm Therapeutics Inc | Phase 1 | Terminated | 33 | Oct 1, 2015 | Registry ↗ |
| Jan 20, 2023 | Study of Safety, Tolerability, and Pharmacokinetics of Topical Selinexor (KPT-330) Diabetic Foot Ul… NCT02367690 · Diabetic Foot Ulcers Selinexor, Standard-of-Care | KPTI Karyopharm Therapeutics Inc | Phase 1/2 | Withdrawn | 0 | May 2015 | Registry ↗ |
37 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 7:46 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances